BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 8978791)

  • 1. [CMF or CAF combination chemotherapy for breast cancer].
    Ota J
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy for recurrent breast carcinoma].
    Taguchi T
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):439-47. PubMed ID: 4004279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment].
    Kubo K; Abe O; Izuo M; Enomoto K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2523-31. PubMed ID: 6689117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
    Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
    Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Systemic chemotherapy of mammary carcinoma: plasma and tissue concentrations of 5-fluorouracil and adriamycin, and result of CAF and CMF therapy of breast cancer].
    Murayama Y; Nagashima M
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):415-9. PubMed ID: 6546655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
    Abe O; Izuo M; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
    Gan To Kagaku Ryoho; 1982 May; 9(5):866-73. PubMed ID: 7184431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy of advanced breast cancer].
    Ogawa M
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):769-74. PubMed ID: 1605652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adriamycin--breast cancer].
    Nomura Y
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1911-5. PubMed ID: 8978796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A double-blind randomized comparative study of oral 5-fluorouracil (5-FU), cyclophosphamide (CPA), and 5-FU + CPA in advanced breast cancer].
    Takayama T; Nomura Y
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):73-80. PubMed ID: 10660736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].
    Honda S; Toi M; Shimizu S; Hayashi K; Tominaga T
    Gan To Kagaku Ryoho; 1997 Apr; 24(6):679-83. PubMed ID: 9126304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer].
    Mitsuyama S; Tashiro H; Koga T; Maehara Y; Ogawa M; Kakegawa T; Shimazu H; Sugimachi K; Tomita M; Nakamura Y
    Gan To Kagaku Ryoho; 1995 Dec; 22(14):2073-80. PubMed ID: 8607618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
    Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
    J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.
    Pronzato P; Amoroso D; Bertelli G; Queirolo P; Sertoli MR; Rosso R
    Anticancer Res; 1990; 10(6):1743-5. PubMed ID: 2126683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.